TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Q-linea AB ( (SE:QLINEA) ) has shared an update.
Q-linea AB has submitted a 510(k) application to the FDA for expanded organism and antimicrobial claims on their ASTar BC G- panel, enhancing its clinical utility for treating bacteremia and sepsis. This move follows a successful clinical trial and aims to align the FDA-cleared panel with its EU counterpart, potentially increasing its adoption in the US market, with a second FDA clearance expected by spring 2026.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK23.50 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea is a company headquartered in Uppsala, Sweden, with regional offices in Italy and the USA, and partnerships worldwide. They specialize in rapid AST systems, particularly the ASTar®, which is designed to accelerate and simplify workflows in treating bloodstream infections and sepsis. Their products aim to reduce the time to optimal antimicrobial therapies, ensuring patients receive correct treatments promptly, thus contributing to sustainable healthcare and safeguarding antibiotic effectiveness.
Average Trading Volume: 13,325
Technical Sentiment Signal: Sell
Current Market Cap: SEK476.8M
For a thorough assessment of QLINEA stock, go to TipRanks’ Stock Analysis page.